As part of our Drugs to Watch™ program, Clarivate oncology experts pored over abstracts submitted to the 2024 ESMO Congress to identify 11 particularly striking results, along with an additional three of import to the fast-growing Mainland China market. Read our new report in which they lay out the context, key findings and potential market impact of each.
This year’s ESMO Drugs to Watch include:
- Adjuvant Tecentriq plus bevacizumab in resected or ablated high-risk hepatocellular carcinoma
- Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda in high-risk stage II-III triple-negative breast cancer
- Perioperative Imfinzi plus chemotherapy in cisplatin-eligible muscle-invasive bladder cancer (MIBC)
- Disitamab vedotin in combination with Keytruda in HER2-expressing locally advanced or metastatic urothelial carcinoma
- Zynyz with carboplatin-paclitaxel in chemotherapy-naive anal cancer
- Mixed phase 2 data for Opdualag in first-line advanced NSCLC
- Truqap plus paclitaxel as first-line treatment of metastatic triple negative breast cancer
- The addition of Lenvima and Keytruda to TACE in intermediate-stage hepatocellular carcinoma
- PSMA-targeted radioligand 177Lu-PNT2002 in mCRPC
- The combination of Cabometyx and Tecentriq in metastatic castration-resistant prostate cancer
- RP1 plus Opdivo in anti-PD-1-failed unresectable or metastatic malignant melanoma
And for Mainland China:
- AnDeWei in combination with anlotinib in previously untreated advanced renal cell carcinoma (RCC)
- QL-1706 in first-line advanced hepatocellular carcinoma (HCC) patients
- SHR-1701 plus chemotherapy as first-line therapy in patients with unresectable locally advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma
